Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells

BACKGROUND: Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8(+) T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Masterman, Kelly-Anne, Haigh, Oscar L, Tullett, Kirsteen M, Leal-Rojas, Ingrid M, Walpole, Carina, Pearson, Frances E, Cebon, Jonathon, Schmidt, Christopher, O'Brien, Liam, Rosendahl, Nikita, Daraj, Ghazal, Caminschi, Irina, Gschweng, Eric H, Hollis, Roger P, Kohn, Donald B, Lahoud, Mireille H, Radford, Kristen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394304/
https://www.ncbi.nlm.nih.gov/pubmed/32737142
http://dx.doi.org/10.1136/jitc-2020-000691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394304/
https://www.ncbi.nlm.nih.gov/pubmed/32737142
http://dx.doi.org/10.1136/jitc-2020-000691

Ejemplares similares